New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment
Results Reported at 9th
Over 7 Million Patients with HIV Worldwide May Benefit from the Reduction in Diarrhea Achieved with Long-Term Mytesi Therapy
Mytesi (crofelemer) is the only drug that has been specifically studied
“Mytesi achieves much greater reductions in HIV-related diarrhea than
was apparent in the ADVENT primary responder analysis,” commented Dr.
Prior to study entry, patients enrolled in the ADVENT trial had an average of 20 watery stools per week (approximately three per day). Key results of this analysis showed:
- An average reduction of 73 percent in diarrhea episodes by week 24 of crofelemer treatment;
- More than 75 percent of patients had a clinically meaningful reduction in diarrhea, as measured by at least a 50 percent decrease in the number of episodes;
- More than 50 percent of patients had a complete resolution of their diarrhea by week 24 of crofelemer treatment;
- There was no significant difference between patients who were taking a protease inhibitor and those who were not or based upon the cause of the diarrhea.
“With an estimated 20 percent of the more than 36 million people
currently living with HIV suffering from diarrhea, there are more than
seven million patients worldwide who may benefit from the reduction in
diarrhea that can be achieved with Mytesi therapy,” said
The poster for this data presentation is available at: http://mytesi.com/clinical-results.html
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the
For more information, please visit www.napopharma.com.
For more information about Jaguar, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the proposed merger between Jaguar and Napo, Jaguar’s intention to develop species-specific formulations of Neonorm™ in additional target species, and the Company’s plan to develop formulations of Canalevia™ for cats, horses and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.